Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Rojo

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Translational Psychiatry|September 21, 2018
A role for APP in Wnt signalling links synapse loss with β-amyloid productionChristina Elliott, Ana I Rojo, Elena Ribe, et al.
Trends in Pharmacological Sciences|July 27, 2020
Can Activation of NRF2 Be a Strategy against COVID-19?Antonio Cuadrado, Marta Pajares, Cristina Benito, et al.
Biomolecules|January 25, 2025
Proteostasis Decline and Redox Imbalance in Age-Related Diseases: The Therapeutic Potential of NRF2Brigitta Buttari, Antonella Tramutola, Ana I Rojo, et al.
Redox Biology|January 10, 2020
Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomasMaribel Escoll, Diego Lastra, Marta Pajares, et al.
Nature Reviews. Drug Discovery|January 6, 2019
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseasesAntonio Cuadrado, Ana I Rojo, Geoffrey Wells, et al.
Redox Biology|January 7, 2024
Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASHRaquel Fernández-Ginés, José Antonio Encinar, Maribel Escoll, et al.
Revista Alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)|June 17, 2009
[Multicenter study of satisfaction with fast-dissolving ebastine, 20 mg/ day, in Mexican patients with allergic rhinitis]Daniel Aguilar, A Arias, Carlos Báez, et al.
Molecular and Cellular Biology|July 4, 2012
Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axisPatricia Rada, Ana I Rojo, Nathalie Evrard-Todeschi, et al.
Scientific Reports|April 1, 2017
Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's diseaseIsabel Gameiro, Patrycja Michalska, Giammarco Tenti, et al.
Cureus|August 6, 2025
Efficacy of Empagliflozin Versus Placebo in Patients With Recent Acute Myocardial Infarction: A Systematic ReviewCarlos A Umaña Mejia, Jose R Flores Valdés, Dominique Alvarado Corletto, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Translational Psychiatry|September 21, 2018
A role for APP in Wnt signalling links synapse loss with β-amyloid productionChristina Elliott, Ana I Rojo, Elena Ribe, et al.
Trends in Pharmacological Sciences|July 27, 2020
Can Activation of NRF2 Be a Strategy against COVID-19?Antonio Cuadrado, Marta Pajares, Cristina Benito, et al.
Biomolecules|January 25, 2025
Proteostasis Decline and Redox Imbalance in Age-Related Diseases: The Therapeutic Potential of NRF2Brigitta Buttari, Antonella Tramutola, Ana I Rojo, et al.
Redox Biology|January 10, 2020
Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomasMaribel Escoll, Diego Lastra, Marta Pajares, et al.
Nature Reviews. Drug Discovery|January 6, 2019
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseasesAntonio Cuadrado, Ana I Rojo, Geoffrey Wells, et al.
Redox Biology|January 7, 2024
Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASHRaquel Fernández-Ginés, José Antonio Encinar, Maribel Escoll, et al.
Revista Alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)|June 17, 2009
[Multicenter study of satisfaction with fast-dissolving ebastine, 20 mg/ day, in Mexican patients with allergic rhinitis]Daniel Aguilar, A Arias, Carlos Báez, et al.
Molecular and Cellular Biology|July 4, 2012
Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axisPatricia Rada, Ana I Rojo, Nathalie Evrard-Todeschi, et al.
Scientific Reports|April 1, 2017
Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's diseaseIsabel Gameiro, Patrycja Michalska, Giammarco Tenti, et al.
Cureus|August 6, 2025
Efficacy of Empagliflozin Versus Placebo in Patients With Recent Acute Myocardial Infarction: A Systematic ReviewCarlos A Umaña Mejia, Jose R Flores Valdés, Dominique Alvarado Corletto, et al.
Pageof 10